38 related articles for article (PubMed ID: 10064193)
1. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Kobrinsky NL; Sposto R; Shah NR; Anderson JR; DeLaat C; Morse M; Warkentin P; Gilchrist GS; Cohen MD; Shina D; Meadows AT
J Clin Oncol; 2001 May; 19(9):2390-6. PubMed ID: 11331317
[TBL] [Abstract][Full Text] [Related]
2. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
Kung FH; Desai SJ; Dickerman JD; Goorin AM; Harris MB; Inoue S; Krischer JP; Murphy SB; Pratt CB; Toledano S
J Pediatr Hematol Oncol; 1995 Aug; 17(3):265-9. PubMed ID: 7620926
[TBL] [Abstract][Full Text] [Related]
4. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.
Cairo M; Auperin A; Perkins SL; Pinkerton R; Harrison L; Goldman S; Patte C
Br J Haematol; 2018 Sep; 182(6):859-869. PubMed ID: 29984828
[TBL] [Abstract][Full Text] [Related]
5. Management of Non-Hodgkin Lymphoma: ICMR Consensus Document.
Thacker N; Bakhshi S; Chinnaswamy G; Vora T; Prasad M; Bansal D; Agarwala S; Kapoor G; Radhakrishnan V; Laskar S; Kaur T; Rath GK; Dhaliwal RS; Arora B
Indian J Pediatr; 2017 May; 84(5):382-392. PubMed ID: 28378140
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents.
Kim H; Park ES; Lee SH; Koo HH; Kim HS; Lyu CJ; Jun SE; Lim YT; Baek HJ; Kook H; Lee JW; Kang HJ; Park KD; Shin HY; Ahn HS
Cancer Res Treat; 2014 Oct; 46(4):358-65. PubMed ID: 25043820
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
Sandlund JT; Pui CH; Mahmoud H; Zhou Y; Lowe E; Kaste S; Kun LE; Krasin MJ; Onciu M; Behm FG; Ribeiro RC; Razzouk BI; Howard SC; Metzger ML; Hale GA; Rencher R; Graham K; Hudson MM
Ann Oncol; 2011 Feb; 22(2):468-71. PubMed ID: 20624787
[TBL] [Abstract][Full Text] [Related]
9. The combination of monoclonal antibodies and conventional chemotherapy for children with malignant lymphoma: Opportunities and challenges.
Sandlund JT
Pediatr Blood Cancer; 2009 Feb; 52(2):150-2. PubMed ID: 19034905
[No Abstract] [Full Text] [Related]
10. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
11. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Haim N; Ben-Shahar M; Epelbaum R
Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
[TBL] [Abstract][Full Text] [Related]
12. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Vose JM
Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
[TBL] [Abstract][Full Text] [Related]
13. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Cairo MS
Semin Oncol; 1995 Jun; 22(3 Suppl 7):23-7. PubMed ID: 7610395
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study.
Kung FH; Harris MB; Krischer JP
Med Pediatr Oncol; 1999 Mar; 32(3):225-6. PubMed ID: 10064193
[No Abstract] [Full Text] [Related]
15. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L
Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
